Chemours Net Worth
Chemours Net Worth Breakdown | CC |
Chemours Net Worth Analysis
Chemours' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Chemours' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Chemours' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Chemours' net worth analysis. One common approach is to calculate Chemours' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Chemours' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Chemours' net worth. This approach calculates the present value of Chemours' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Chemours' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Chemours' net worth. This involves comparing Chemours' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Chemours' net worth relative to its peers.
Enterprise Value |
|
To determine if Chemours is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Chemours' net worth research are outlined below:
| Chemours generated a negative expected return over the last 90 days | |
| Chemours Co reports about 1.1 B in cash with (633 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.73. | |
| Over 86.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thefly.com: Chemours price target lowered by 4 at Barclays, heres why CC |
Chemours uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Chemours Co. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Chemours' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of February 2024 Upcoming Quarterly Report | View | |
| 25th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Chemours Target Price Consensus
Chemours target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Chemours' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 9 | Buy |
Most Chemours analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Chemours stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Chemours, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationChemours Target Price Projection
Chemours' current and average target prices are 15.80 and 24.22, respectively. The current price of Chemours is the price at which Chemours Co is currently trading. On the other hand, Chemours' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Chemours Market Quote on 25th of February 2025
Target Price
Analyst Consensus On Chemours Target Price
Know Chemours' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Chemours is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Chemours Co backward and forwards among themselves. Chemours' institutional investor refers to the entity that pools money to purchase Chemours' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2024-12-31 | 2.1 M | Norges Bank | 2024-12-31 | 1.8 M | Dimensional Fund Advisors, Inc. | 2024-12-31 | 1.8 M | American Century Companies Inc | 2024-12-31 | 1.6 M | Massachusetts Financial Services Company | 2024-12-31 | 1.6 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.6 M | Vision One Management Partners Lp | 2024-12-31 | 1.6 M | Scopia Management Inc | 2024-12-31 | 1.4 M | Charles Schwab Investment Management Inc | 2024-12-31 | 1.3 M | Blackrock Inc | 2024-12-31 | 16.8 M | Vanguard Group Inc | 2024-12-31 | 15.2 M |
Follow Chemours' market capitalization trends
The company currently falls under 'Mid-Cap' category with a market capitalization of 2.5 B.Market Cap |
|
Project Chemours' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.01 | 0.01 | |
| Return On Capital Employed | 0.08 | 0.13 | |
| Return On Assets | 0.01 | 0.01 | |
| Return On Equity | 0.14 | 0.18 |
When accessing Chemours' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Chemours' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Chemours' profitability and make more informed investment decisions.
Please note, the presentation of Chemours' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Chemours' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Chemours' management manipulating its earnings.
Evaluate Chemours' management efficiency
Chemours has Return on Asset (ROA) of 0.0349 % which means that for every $100 of assets, it generated a profit of $0.0349. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.128 %, which means that it produced $0.128 on every 100 dollars invested by current stockholders. Chemours' management efficiency ratios could be used to measure how well Chemours manages its routine affairs as well as how well it operates its assets and liabilities. At present, Chemours' Return On Equity is projected to slightly decrease based on the last few years of reporting. At present, Chemours' Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 0.62, whereas Non Current Assets Total are forecasted to decline to about 4.5 B.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.05 | 3.84 | |
| Tangible Book Value Per Share | 3.72 | 7.43 | |
| Enterprise Value Over EBITDA | 8.91 | 8.66 | |
| Price Book Value Ratio | 4.18 | 8.14 | |
| Enterprise Value Multiple | 8.91 | 8.66 | |
| Price Fair Value | 4.18 | 8.14 | |
| Enterprise Value | 6.2 B | 5.3 B |
Chemours showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Enterprise Value Revenue 1.0631 | Revenue | Quarterly Revenue Growth (0.01) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Chemours insiders, such as employees or executives, is commonly permitted as long as it does not rely on Chemours' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Chemours insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kava Joseph Daniel over a month ago Insider Trading | ||
Kristine Wellman over two months ago Acquisition by Kristine Wellman of 20671 shares of Chemours at 27.5 subject to Rule 16b-3 | ||
Picho Diane I. over three months ago Disposition of tradable shares by Picho Diane I. of Chemours at 19.04 subject to Rule 16b-3 | ||
Alvenia Scarborough over three months ago Acquisition by Alvenia Scarborough of 7903 shares of Chemours at 27.5 subject to Rule 16b-3 | ||
Shane Hostetter over six months ago Acquisition by Shane Hostetter of 26709 shares of Chemours subject to Rule 16b-3 | ||
Hostetter Shane over six months ago Insider Trading | ||
Camela Wisel over a year ago Acquisition by Camela Wisel of 5425 shares of Chemours subject to Rule 16b-3 |
Chemours Corporate Filings
F3 | 19th of February 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 18th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 7th of February 2025 Other Reports | ViewVerify | |
8K | 2nd of December 2024 An amendment to a previously filed Form 8-K | ViewVerify |
Chemours Earnings Estimation Breakdown
The calculation of Chemours' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Chemours is estimated to be 0.2112 with the future projection ranging from a low of 0.15 to a high of 0.36. Please be aware that this consensus of annual earnings estimates for Chemours Co is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.15 Lowest | Expected EPS | 0.36 Highest |
Chemours Earnings Projection Consensus
Suppose the current estimates of Chemours' value are higher than the current market price of the Chemours stock. In this case, investors may conclude that Chemours is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Chemours' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 10 | 63.46% | 0.11 | 0.2112 | 0.57 |
Chemours Earnings History
Earnings estimate consensus by Chemours analysts from Wall Street is used by the market to judge Chemours' stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Chemours' upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.Chemours Quarterly Gross Profit |
|
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Chemours' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Chemours Earnings per Share Projection vs Actual
Actual Earning per Share of Chemours refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Chemours Co predict the company's earnings will be in the future. The higher the earnings per share of Chemours, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Chemours Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Chemours, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Chemours should always be considered in relation to other companies to make a more educated investment decision.Chemours Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Chemours' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-26 | 2024-12-31 | 0.1559 | 0.11 | -0.0459 | 29 | ||
2024-11-04 | 2024-09-30 | 0.28 | 0.4 | 0.12 | 42 | ||
2024-08-01 | 2024-06-30 | 0.57 | 0.38 | -0.19 | 33 | ||
2024-04-30 | 2024-03-31 | 0.18 | 0.32 | 0.14 | 77 | ||
2024-03-27 | 2023-12-31 | 0.25 | 0.31 | 0.06 | 24 | ||
2023-10-26 | 2023-09-30 | 0.69 | 0.63 | -0.06 | 8 | ||
2023-07-27 | 2023-06-30 | 1.07 | 1.1 | 0.03 | 2 | ||
2023-04-27 | 2023-03-31 | 0.47 | 0.98 | 0.51 | 108 | ||
2023-02-09 | 2022-12-31 | 0.08 | -0.6465 | -0.7265 | 908 | ||
2022-10-25 | 2022-09-30 | 1.04 | 1.24 | 0.2 | 19 | ||
2022-07-28 | 2022-06-30 | 1.43 | 1.89 | 0.46 | 32 | ||
2022-05-02 | 2022-03-31 | 0.92 | 1.46 | 0.54 | 58 | ||
2022-02-10 | 2021-12-31 | 0.92 | 0.81 | -0.11 | 11 | ||
2021-11-04 | 2021-09-30 | 1.02 | 1.27 | 0.25 | 24 | ||
2021-07-29 | 2021-06-30 | 0.94 | 1.2 | 0.26 | 27 | ||
2021-05-03 | 2021-03-31 | 0.63 | 0.71 | 0.08 | 12 | ||
2021-02-11 | 2020-12-31 | 0.41 | 0.61 | 0.2 | 48 | ||
2020-11-03 | 2020-09-30 | 0.33 | 0.47 | 0.14 | 42 | ||
2020-07-30 | 2020-06-30 | 0.1 | 0.18 | 0.08 | 80 | ||
2020-05-05 | 2020-03-31 | 0.46 | 0.71 | 0.25 | 54 | ||
2020-02-13 | 2019-12-31 | 0.42 | 0.56 | 0.14 | 33 | ||
2019-11-04 | 2019-09-30 | 0.59 | 0.59 | 0.0 | 0 | ||
2019-08-01 | 2019-06-30 | 0.86 | 0.72 | -0.14 | 16 | ||
2019-05-02 | 2019-03-31 | 0.9 | 0.63 | -0.27 | 30 | ||
2019-02-14 | 2018-12-31 | 0.99 | 1.05 | 0.06 | 6 | ||
2018-11-01 | 2018-09-30 | 1.42 | 1.49 | 0.07 | 4 | ||
2018-08-02 | 2018-06-30 | 1.59 | 1.71 | 0.12 | 7 | ||
2018-05-03 | 2018-03-31 | 1.22 | 1.41 | 0.19 | 15 | ||
2018-02-14 | 2017-12-31 | 0.97 | 1.19 | 0.22 | 22 | ||
2017-11-02 | 2017-09-30 | 1.04 | 1.12 | 0.08 | 7 | ||
2017-08-02 | 2017-06-30 | 0.85 | 0.87 | 0.02 | 2 | ||
2017-05-01 | 2017-03-31 | 0.5 | 0.75 | 0.25 | 50 | ||
2017-02-15 | 2016-12-31 | 0.29 | 0.35 | 0.06 | 20 | ||
2016-11-06 | 2016-09-30 | 0.34 | 0.61 | 0.27 | 79 | ||
2016-08-08 | 2016-06-30 | 0.17 | 0.27 | 0.1 | 58 | ||
2016-05-02 | 2016-03-31 | 0.02 | 0.06 | 0.04 | 200 | ||
2016-02-23 | 2015-12-31 | 0.08 | 0.16 | 0.08 | 100 | ||
2015-11-05 | 2015-09-30 | 0.26 | 0.19 | -0.07 | 26 | ||
2015-08-06 | 2015-06-30 | 0.33 | 0.24 | -0.09 | 27 |
Chemours Corporate Directors
| Curtis Anastasio | Independent Director | Profile | |
| Curtis Crawford | Independent Director | Profile | |
| Mary Cranston | Independent Director | Profile | |
| Bradley Bell | Independent Director | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Chemours Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Diversified Chemicals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chemours. If investors know Chemours will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chemours listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.65) | Dividend Share 1 | Earnings Share 0.57 | Revenue Per Share | Quarterly Revenue Growth (0.01) |
The market value of Chemours is measured differently than its book value, which is the value of Chemours that is recorded on the company's balance sheet. Investors also form their own opinion of Chemours' value that differs from its market value or its book value, called intrinsic value, which is Chemours' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chemours' market value can be influenced by many factors that don't directly affect Chemours' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chemours' value and its price as these two are different measures arrived at by different means. Investors typically determine if Chemours is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chemours' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.